Ascendis Pharma A/S (ASND)

How it makes money

Almost all the money comes from selling two specialty medicines that patients take chronically: 683.6 million euros of the 720.1 million euros of 2025 revenue was product sales. In the United States and in a handful of European countries where it has built its own commercial organisation, Ascendis sells directly through specialty distributors and is paid by health insurers and public payors; elsewhere it sells through exclusive distribution agreements with local market leaders, or leaves the market to a licensing partner. The remainder of revenue is lumpy and non-recurring: upfront licence fees, development and regulatory milestones, and reimbursement for research services and clinical supply provided to partners such as Novo Nordisk, Teijin, VISEN and Eyconis. Two synthetic royalty agreements with Royalty Pharma, which sold 9.15% of U.S. SKYTROFA net sales and 3.0% of U.S. YORVIPATH net sales in exchange for 150 million dollars each, are financing liabilities rather than revenue, and reduce the cash the company keeps from its own U.S. sales.

Revenue by segment

What protects Ascendis is legal and regulatory rather than commercial: patents on the TransCon linker chemistry, and orphan drug exclusivity granted by the FDA — seven years for YORVIPATH in adult hypoparathyroidism from September 2024, and exclusivity for SKYTROFA in its approved indications. Other than the rights granted to its partners, the company holds worldwide rights to the platform and owes no third-party royalties on it. The protection is real but bounded: the company itself warns in its risk factors that orphan exclusivity does not stop a different drug being approved for the same rare condition, and it names Novo Nordisk's SOGROYA and Pfizer's NGENLA as approved weekly competitors in growth hormone, plus several companies working on rival long-acting delivery platforms. Rare-disease prescribing also carries some switching friction once a patient is stabilised on a therapy, but nothing in the filing quantifies it.

Demand does not follow the economy. Hypoparathyroidism and growth hormone deficiency are chronic conditions: once a patient is diagnosed and starts therapy, treatment continues for years and is paid for by insurers or public health systems, not out of a household budget that shrinks in a recession. What actually drives the top line is the number of patients diagnosed and enrolled — the filing reports the count of unique patients and prescribing physicians as the operational measure — plus reimbursement decisions country by country and the timing of new approvals and label expansions. The volatile part of revenue is not the medicines but the licence and milestone line, which depends on when a partner signs or reaches a development step: it fell from 122.3 million euros in 2024 to 5.6 million in 2025.

Key risks

• The company may keep losing money — Ascendis states that it may incur significant losses in the future, which makes it difficult to assess its future viability, and that losses or profits may swing so much from quarter to quarter that comparing one period with another is not meaningful. It confirmed this in 2025 with an operating loss of 136.3 million euros and a net loss of 228.0 million euros despite record revenue.
• Dependence on a handful of products and on one technology — The company says it is substantially dependent on the success of its products and product candidates, and that it relies significantly on its TransCon technologies. Almost all revenue comes from YORVIPATH and SKYTROFA; a setback affecting the platform, or either product, hits the whole business at once.
• Clinical development can fail or slip — Ascendis warns that clinical drug development is lengthy, expensive and uncertain, that it may face substantial delays in its studies, and that results of earlier trials may not predict later ones. It adds that interim, top-line and preliminary data it publishes may change materially once all patient data are audited and verified.
• Reimbursement is not guaranteed — The filing flags that coverage and reimbursement by third-party payors for newly approved products is uncertain, and that failing to obtain or keep adequate coverage would limit the ability to market a product and reduce revenue. Revenue is also stated net of a range of sales deductions negotiated with payors and government programmes.
• Manufacturing depends on third parties and single-source suppliers — The company relies on third parties to manufacture preclinical, clinical and commercial supplies of its products and their device components, and states that the parent drug, drug product and other components are acquired from certain single-source suppliers whose loss or failure to supply could materially harm the business.
• Intense competition and intellectual property litigation — Ascendis states that competition in biotechnology and pharmaceuticals is intense and that competitors may discover, develop or commercialise products faster or more successfully. It also warns that being sued for allegedly infringing third-party intellectual property would be costly and time consuming and that an unfavourable outcome could harm the business.
• May need to raise capital again — The company says it may seek additional financing and that failing to obtain it on acceptable terms could force it to delay, limit, scale back or cease commercialisation, development or other operations, and that raising capital may dilute shareholders or require relinquishing rights to products — as it already did through the two Royalty Pharma royalty sales.

The filing discloses that for the year ended 31 December 2025 two commercial customers each represented more than 10% of revenue from commercial products, down from four such customers in 2024 and 2023, but it does not state their combined share, so no figure can be given. These customers are specialty distributors and wholesalers, not the patients: as is normal for specialty pharmaceuticals, a small number of intermediaries handles the flow to a wide base of prescribers. Geographically the concentration is clearer — 546.4 million euros of the 720.1 million euros of 2025 revenue came from the United States.